Penetrium Bioscience Inc. (KOSDAQ:187660)
South Korea · Delayed Price · Currency is KRW 10,370
-140 (-1.33%)
At close: Apr 3, 2026
Penetrium Bioscience Revenue
In the year 2024, Penetrium Bioscience had annual revenue of 9.74B KRW, down -29.33%.
Revenue
9.74B
Revenue Growth
-29.33%
P/S Ratio
59.06
Revenue / Employee
60.91M
Employees
160
Market Cap
575.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.74B | -4.05B | -29.33% |
| Dec 31, 2023 | 13.79B | -1.09B | -7.34% |
| Dec 31, 2022 | 14.88B | 904.78M | 6.47% |
| Dec 31, 2021 | 13.98B | 857.61M | 6.54% |
| Dec 31, 2020 | 13.12B | 2.91B | 28.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HLB bioStep | 74.05B |
| DreamCIS | 66.63B |
| C&R Research | 64.98B |
| DT&CRO CO. | 47.75B |
| WOOJUNG BIO | 37.59B |
| BioInfra | 23.15B |
| P&K Skin Research Center | 22.78B |
| Curachem | 6.02B |